Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor with Therapeutic potential for the prevention or treatment of an expanding number of gastrointestinal diseases, including short bowel syndrome (SBS). Teduglutide, being developed by NPS Allelix and licensee Nycomed, is a protease-Resistant analog of GLP-2 for the potential treatment of gastrointestinal disease. Teduglutide has prolonged biological activity compared with native GLP-2, and preclinical studies demonstrated significant intestinotrophic activity in models of SBS, experimental colitis and chemoTherapy-induced intestinal mucositis. Patients with SBS rely on parenteral nutrition (PN) following bowel Resection, and in a phase III clinical trial with teduglutide, > 20% reduction in PN was observed in patients with SBS receiving teduglutide. A phase II clinical trial for teduglutide in Crohn's disease observed remission rates of 55.6% in patients. At the time of publication, phase III clinical Trials for SBS were ongoing, as were preclinical studies for chemoTherapy-induced mucositis and pediatric indications. Teduglutide repResents a novel, efficacious Drug capable of increasing intestinal growth and improving intestinal function, and may change clinical management of intestinal disease and damage.
|Number of pages||12|
|Journal||CURRENT OPINION IN MOLECULAR THERAPEUTICS|
|Publication status||Published - Dec 2010|